Key result
Advancing pediatric CKD and systolic hypertension are linked to subclinical CVD and ~48% stage 5 LVH.
Why the study?
Cardiovascular disease is the most important comorbidity affecting long-term survival in children with CKD, but detailed cardiovascular phenotypes and associated variables were not fully characterized.
Cohort (n=688)
Yes
In children with CKD, subclinical cardiovascular disease is highly prevalent and strongly associated with systolic hypertension and advancing CKD stage.
May support intensified BP surveillance in advanced pediatric CKD; leaves open whether hypertension control alters LVH progression.
BACKGROUND AND OBJECTIVES: Cardiovascular disease is the most important comorbidity affecting long-term survival in children with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: . The cardiovascular status is monitored annually, and subclinical cardiovascular disease is assessed by noninvasive measurements of surrogate markers, including the left ventricular mass index, carotid intima-media thickness, and central pulse wave velocity. We here report baseline data at study entry and an explorative analysis of variables associated with surrogate markers. RESULTS: A total of 737 patients were screened from October of 2009 to August of 2011 in 55 centers in 12 European countries, and baseline data were analyzed in 688 patients. Sixty-four percent had congenital anomalies of the kidney and urinary tract; 26.1% of children had uncontrolled hypertension (24-hour ambulatory BP monitoring; n=545), and the prevalence increased from 24.4% in CKD stage 3 to 47.4% in CKD stage 5. The prevalence of left ventricular hypertrophy was higher with each CKD stage, from 10.6% in CKD stage 3a to 48% in CKD stage 5. Carotid intima-media thickness was elevated in 41.6%, with only 10.8% of patients displaying measurements below the 50th percentile. Pulse wave velocity was increased in 20.1%. The office systolic BP SD score was the single independent factor significantly associated with all surrogate markers of cardiovascular disease. The intermediate end point score (derived from the number of surrogate marker measurements >95th percentile) was independently associated with a diagnosis of congenital anomalies of the kidney and urinary tract, time since diagnosis of CKD, body mass index, office systolic BP, serum phosphorus, and the hemoglobin level. CONCLUSIONS: The baseline data of this large pediatric cohort show that surrogate markers for cardiovascular disease are closely associated with systolic hypertension and stage of CKD.
No takes yet. Share an insight, caveat, or question.
Schaefer et al. (2016) conducted a cohort in Chronic Kidney Disease (n=688). CKD stage and systolic blood pressure was evaluated on Surrogate markers of cardiovascular disease (left ventricular mass index, carotid intima-media thickness, central pulse wave velocity). In children with CKD, cardiovascular disease surrogate markers were closely associated with systolic hypertension and CKD stage, with LVH prevalence rising from 10.6% in stage 3a to 48% in stage 5.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: